2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Microsomal Triglyceride Transfer Protein (MTP)
  5. Microsomal Triglyceride Transfer Protein (MTP) Inhibitor

Microsomal Triglyceride Transfer Protein (MTP) Inhibitor

Microsomal Triglyceride Transfer Protein (MTP) Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-14667
    Lomitapide
    		Inhibitor 99.63%
    Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.
  • HY-14668
    Lomitapide mesylate
    		Inhibitor 99.61%
    Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8+ T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia.
  • HY-106011
    SLX-4090
    		Inhibitor 98.97%
    SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia.
  • HY-116630
    Usistapide
    		Inhibitor
    Usistapide (JNJ-16269110) is a microsomal triglyceride transfer protein (MTP) inhibitor. Usistapide is promising for research of obesity.
  • HY-177291
    LAB687
    		Inhibitor
    LAB687 is a microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 0.9 nM for apolipoprotein B (apoB) secretion in HepG2 cells. LAB687 also acts as a Smoothened (Smo) antagonist, with IC50 values of 2.48 μM and 3.42 μM against mouse and human Smo receptors, respectively. LAB687 reduces triglyceride and low-density lipoprotein cholesterol (LDL-C) levels, and inhibits the Hedgehog signaling pathway. LAB687 can be used in studies related to Hedgehog-dependent cancers.
  • HY-14667S1
    Lomitapide-d4
    		Inhibitor
    Lomitapide-d4 (AEGR-733-d4) is deuterium labeled Lomitapide. Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.
  • HY-14667R
    Lomitapide (Standard)
    		Inhibitor
    Lomitapide (Standard) is the analytical standard of Lomitapide. This product is intended for research and analytical applications. Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.
  • HY-106011R
    SLX-4090 (Standard)
    		Inhibitor
    SLX-4090 (Standard) is the analytical standard of SLX-4090 (HY-106011). This product is intended for research and analytical applications. SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia.
  • HY-119220
    Granotapide
    		Inhibitor
    Granotapide is an orally active microsomal triglyceride transfer protein (MTP) inhibitor. Granotapide reduces the absorption of cholesterol and triglycerides by inhibiting MTP. Granotapide can be used in the research of coronary artery disease, obesity, diabetes mellitus and hypertension.